Radius Reports Positive Phase 3 Results For TYMLOS Subcutaneous Injection In Males With Osteoporosis
(RTTNews) - Radius Health Inc. (RDUS) announced positive results from the ATOM Phase 3 Study evaluating TYMLOS or abaloparatide 80mcg subcutaneous (SC) for use in males with osteoporosis. The company ...
SAN DIEGO -- Treatment with abaloparatide (Tymlos) was safe and effective for men with osteoporosis, according to the phase III ATOM trial. Compared with a 1.2% increase with placebo, men randomized ...
Results showed that treatment with abaloparatide for 12 months resulted in significant increases in bone mineral density compared with placebo. The Food and Drug Administration (FDA) has approved ...
Radius Health, Inc. RDUS announced that it has entered into an agreement with Paladin Labs Inc., an operating company of Endo International plc ENDP to register, commercialize and distribute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback